Prostate cancer stem cell biology

Minerva Urologica e Nefrologica

Volumn 64, Issue 1, 2012, Pages 19-33

  Yu, C ^a,b   Yao, Z ^b   Jiang, Y ^a,b   Keller, E T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Biological markers; MicroRNAs; Neoplasm metastasis; Neoplastic stem cell; Prostatic neoplasms

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; CD24 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; HERMES ANTIGEN; MICRORNA; MICRORNA 107; MICRORNA 128; MICRORNA 16; NOTCH RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN LET 7; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; BASAL CELL; CANCER STEM CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MALE; MICRORNAS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84860294303     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11. (Pubitemid 33041634)
2. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005;5:311-21. (Pubitemid 40488636)
3. Clarke M. Cancer Stem Cells - Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006;66:9339-44.
4. Wang ZA, Shen MM. Revisiting the concept of cancer stem cells in prostate cancer. Oncogene 2011;30:1261-71.
5. Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G, Schneider-Broussard R et al. Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 2007;46:1-14. (Pubitemid 46095228)
6. Jemal A SR, Ward E, et al. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
7. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45. (Pubitemid 33741879)
8. Man YG, Gardner WA. Bad seeds produce bad crops: a single stage-process of prostate tumor invasion. Int J Biol Sci 2008;4:246-58.
9. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65:5506-11. (Pubitemid 40911148)
10. Soltanian s. Cancer stem cells and cancer therapy. Tumor biol 2011;32.
11. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-7. (Pubitemid 27298715)
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
13. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-13.
14. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5.
15. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73. (Pubitemid 46349843)
16. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-67. (Pubitemid 350056407)
17. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010;140:62-73.
18. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011-21. (Pubitemid 39331011)
19. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005;121:823-35. (Pubitemid 40806415)
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5. (Pubitemid 46067311)
21. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63. (Pubitemid 47175279)
22. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
23. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. Identification of cells initiating human melanomas. Nature 2008;451:345-9.
24. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67:3153-61. (Pubitemid 46724852)
25. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2betal+ cell population is enriched in tumor-initiating cells. Cancer Res 2007;67:6796-805. (Pubitemid 47105527)
26. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51. (Pubitemid 41713363)
27. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-8. (Pubitemid 46154721)
28. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A 2006;103:11154-9. (Pubitemid 44156488)
29. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14. (Pubitemid 351267301)
30. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994;367:645-8. (Pubitemid 24067706)
31. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008;112:568-75.
32. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010;115:1976-84.
33. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009;101:350-9.
34. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
35. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-56. (Pubitemid 46890873)
36. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-18.
37. Cui F, Wang J, Chen D, Chen YJ. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 2011;25:701-8.
38. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, Nguyen ML et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124:1312-21.
39. Shi MF, Jiao J, Lu WG, Ye F, Ma D, Dong QG, et al. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell Mol Life Sci 2010;67:3915-25.
40. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
41. Penumatsa K, Edassery SL, Barua A, Bradaric MJ, Luborsky JL. Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors. J Ovarian Res 2010;3:28.
42. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z et al. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010;19:327-37.
43. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009;13:2236-52.
44. Yeung J, Esposito MT, Gandillet A, Zeisig BB, Griessinger E, Bonnet D et al. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 2010;18:606-18.
45. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67. (Pubitemid 39063268)
46. Dierks C, Beigi R, Guo GR, Zirlik K, Stegert MR, Manley P et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008;14:238-49.
47. Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007;12:528-41. (Pubitemid 350199070)
48. Armstrong F, Brunet de la Grange P, Gerby B, Rouyez MC, Calvo J, Fontenay M et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009;113:1730-40.
49. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006;66:7445-52. (Pubitemid 44289197)
50. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG et al. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007;99:616-27. (Pubitemid 47073543)
51. Wang Z, Ahmad A, Li Y, Azmi AS, Miele L, Sarkar FH. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res 2011;31:1105-13.
52. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010;70:9937-48.
53. Gulino A, Ferretti E, De Smaele E. Hedgehog signalling in colon cancer and stem cells. EMBO Mol Med 2009;1:300-2.
54. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-9.
55. O'Toole SA, Swarbrick A, Sutherland RL. The Hedge-hog signalling pathway as a therapeutic target in early breast cancer development. Expert Opin Ther Targets 2009;13:1095-103.
56. Peacock CD, Wang Q, Gesell GS, Corcoran-Schwartz IM, Jones E, Kim J et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A 2007;104:4048-53. (Pubitemid 47181576)
57. Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007;67:2187-96. (Pubitemid 46424238)
58. Bar EE, Chaudhry A, Lin A, Fan X, Schreck K, Matsui W et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25:2524-33. (Pubitemid 47582744)
59. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-71.
60. Matsui W. Cancer stem cell targeting in multiple myeloma by grn 163 1, a novel and potent telomerase inhibitor. Blood (ASH Annu Meet Abstr) 2006;108:2540.
61. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003;423:302-5. (Pubitemid 40852701)
62. Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007;110:4427-35. (Pubitemid 351377809)
63. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001;98:2301-7.
64. Battel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
65. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6.857-66.
66. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23. (Pubitemid 350235025)
67. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009;138:592-603.
68. Gal H, Pandi G, Kanner AA, Ram Z, Lithwick-Yanai G, Amariglio N et al. MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun 2008;376:86-90.
69. JiJ, Yamashita T, Budhu A, Forgues M, Jia HL, Li C et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 2009;50:472-80.
70. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010;29:4194-204.
71. Ibarra I, Erlich Y, Muthuswamy SK, Sachidanandam R, Hannon GJ. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genes Dev 2007;21:3238-43. (Pubitemid 350277751)
72. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69:7569-76.
73. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907. (Pubitemid 351482843)
74. Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007;117:2044-50. (Pubitemid 47219544)
75. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-34.
76. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009;69:787-98.
77. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCAl mutation carriers. Nat Med 2009;15:907-13
78. English HF, Santen RJ, Isaacs JT. Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate. 1987;11:229-42. (Pubitemid 18004762)
79. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL et al. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A 1997;94:10705-10. (Pubitemid 27430798)
80. Tsujimura A, Koikawa Y, Salm S, Takao T, Coetzee S, Moscatelli D et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002;157:1257-65. (Pubitemid 34851270)
81. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A 2007;104:181-6. (Pubitemid 46068005)
82. Liao CP, Adisetiyo H, Liang M, Roy-Burman P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 2010;70:7294-303.
83. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, Wu H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 2006;103:1480-5. (Pubitemid 43191191)
84. Maitland NJ, Frame FM, Poison ES, Lewis JL, Collins AT. Prostate cancer stem cells: do they have a basal or luminal phenotype? Horm Cancer 2011;2:47-61.
85. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-71.
86. Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J, Witte ON. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 2010;107:2610-5.
87. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8. (Pubitemid 41528150)
88. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008;9:R83.
89. Rajasekhar VK, Studer L, Gerald W, Socci ND, Scher HI. Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2011;2:162.
90. Korsten H, Ziel-van der Made A, Ma X, van der Kwast T, Trapman J. Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model. PLoS One 2009;4:e5662.
91. Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H, Halili MV et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009;461:495-500.
92. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902. (Pubitemid 37500174)
93. Miki J, Rhim JS. Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 2008;11:32-9. (Pubitemid 351250327)
94. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
95. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756-65. (Pubitemid 351272625)
96. Rybak AP, He L, Kapoor A, Cutz JC, Tang D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim Biophys Acta 2011;1813:683-94.
97. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45. (Pubitemid 39206394)
98. Wei C, Guomin W, Yujun L, Ruizhe Q. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Cancer Biol Ther 2007;6:763-8. (Pubitemid 47328359)
99. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68:9703-11.
100. Pfeiffer MJ, Schalken JA. Stem cell characteristics in prostate cancer cell lines. Eur Urol 2010;57:246-54.
101. Yoshida A, Hsu LC, Dave V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme. 1992;46:239-44. (Pubitemid 23047772)
102. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z et al. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 2010;90:234-44.
103. Burger PE, Gupta R, Xiong X, Ontiveros CS, Salm SN, Moscatelli D et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells 2009;27:2220-8.
104. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzman-Ramirez N et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70:5163-73.
105. Yu C, Yao Z, Dai J, Zhang H, Escara-Wilke J, Zhang X et al. ALDH activity indicates increased tumorigenic cells, but not cancer stem cells, in prostate cancer cell lines. In Vivo 2011;25:69-76.
106. Pellegrini G, Ranno R, Stracuzzi G, Bondanza S, Guerra L, Zambruno G et al. The control of epidermal stem cells (holoclones) in the treatment of massive full-thickness burns with autologous keratinocytes cultured on fibrin. Transplantation 1999;68:868-79. (Pubitemid 29468207)
107. Doherty RE, Haywood-Small SL, Sisley K, Cross NA. Aldehyde dehydrogenase activity selects for the holoclone phenotype in prostate cancer cells. Biochem Biophys Res Commun 2011;414:801-7.
108. Draper JS, Pigott C, Thomson JA, Andrews PW. Surface antigens of human embryonic stem cells: changes upon differentiation in culture. J Anat 2002;200:249-58. (Pubitemid 34467317)
109. Ang J, Lijovic M, Ashman LK, Kan K, Frauman AG. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 2004;13:1717-21. (Pubitemid 39482947)
110. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A 2011;108:1397-402.
111. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81. (Pubitemid 36886244)
112. MA W. Neoplastic lesions of the prostate and seminal vesicles. Genitourinary Tract Pathology. 1993;14:1-.8.
113. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J et al. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010;70:875-82.
114. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis 2009;26:433-46.
115. Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2011.
116. Guzman-Ramirez N, Voller M, Wetterwald A, Germann M, Cross NA, Rentsch CA et al. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009;69:1683-93.
117. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One 2011;6:e22118.
118. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP, Jr., Kaur P et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004;10:2466-72. (Pubitemid 38445708)
119. Fodde R, Brabletz T. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007;19:150-8. (Pubitemid 46386404)
120. Bisson I, Prowse DM. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009;19:683-97.
121. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-9. (Pubitemid 36896715)
122. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011;17:211-5.